# Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO)

> **NCT04061421** · PHASE1,PHASE2 · RECRUITING · sponsor: **Michael Savona** · enrollment: 94 (estimated)

## Conditions studied

- MDS/MPN

## Interventions

- **DRUG:** ASTX727
- **DRUG:** Itacitinib
- **DRUG:** Ruxolitinib

## Key facts

- **NCT ID:** NCT04061421
- **Lead sponsor:** Michael Savona
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-11-24
- **Primary completion:** 2027-08
- **Final completion:** 2027-12
- **Target enrollment:** 94 (ESTIMATED)
- **Last updated:** 2026-04-21

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04061421

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04061421, "Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO)". Retrieved via AI Analytics 2026-08-17 from https://api.ai-analytics.org/clinical/NCT04061421. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*